IPHA · NASDAQ

Innate Pharma SA (IPHA) Stock Price & Fundamentals

$733.88+1.74%+$12.57End-of-day price as of Oct 9, 2026

Sample prices

Prices on this page are generated sample data for development, not real market data, so market cap, P/E and dividend yield are illustrative too. Fundamentals are real, from Innate Pharma SA's SEC filings.

Innate Pharma SA (IPHA) closed at $733.88 on Oct 9, 2026, up 1.74% from the previous close of $721.31.

Share price, past year

1Y +22.39%

Daily closing prices

52-week range $585.47 – $788.07.

Monthly closing prices

Last closing price of each month
Date	Close
Oct 9, 2026	$733.88
Sep 30, 2026	$717.98
Aug 31, 2026	$770.04
Jul 31, 2026	$762.11
Jun 30, 2026	$766.19
May 29, 2026	$724.28
Apr 30, 2026	$658.89
Mar 31, 2026	$659.40
Feb 27, 2026	$656.72
Jan 30, 2026	$665.05
Dec 31, 2025	$612.14
Nov 28, 2025	$598.60
Oct 31, 2025	$623.05

Key statistics

Market cap: —
P/E (TTM): —
EPS (TTM): —
Revenue (TTM): —
Net income (TTM): —
Shares outstanding: 93.7M
Dividend yield: —
52-week range: $585.47 – $788.07

Market cap, P/E and dividend yield aren't shown for Innate Pharma SA yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US, and report in euros.

Financials

Innate Pharma SA reported revenue of €9.01M for fiscal 2025, down 55.25% from fiscal 2024.

Figures are in euros (EUR), as Innate Pharma SA reports them to the SEC.

Annual revenue

FY17FY18FY19FY20FY21FY22FY23FY24FY25

Innate Pharma SA annual financials by fiscal year, from SEC filings
Fiscal year	Revenue	Growth	Net income	Net margin	EPS (diluted)	Free cash flow
FY2025ended Dec 31, 2025	€9.01M	−55.3%	—	—	−€0.55	−€52.90M
FY2024ended Dec 31, 2024	€20.12M	−67.4%	—	—	−€0.61	−€7.29M
FY2023ended Dec 31, 2023	€61.64M	+6.9%	—	—	−€0.09	−€32.91M
FY2022ended Dec 31, 2022	€57.67M	+133.5%	—	—	−€0.73	−€19.69M
FY2021ended Dec 31, 2021	€24.70M	−64.6%	—	—	−€0.66	−€59.39M
FY2020ended Dec 31, 2020	€69.77M	−18.4%	—	—	−€0.81	−€52.67M
FY2019ended Dec 31, 2019	€85.45M	−9.1%	—	—	−€0.31	€33.65M
FY2018ended Dec 31, 2018	€93.95M	+113.4%	—	—	€0.05	−€33.40M
FY2017ended Dec 31, 2017	€44.03M	—	—	—	−€0.89	−€51.02M

Company profile

Name: Innate Pharma SA
Ticker: IPHA
Exchange: NASDAQ
Industry (SEC SIC): Biological Products, (No Diagnostic Substances)
Headquarters: 117 Avenue De Luminy, Bp 30191, Marseille, 13009
Incorporated in: I0
Fiscal year ends: December
SEC CIK: 0001598599

Recent SEC filings

20-FAnnual report for period ending Dec 31, 2025
Apr 1, 2026
20-FAnnual report for period ending Dec 31, 2024
Apr 30, 2025
20-FAnnual report for period ending Dec 31, 2023
Apr 4, 2024
20-F/AAnnual report for period ending Dec 31, 2022
Apr 20, 2023
20-FAnnual report for period ending Dec 31, 2022
Apr 6, 2023
20-FAnnual report for period ending Dec 31, 2021
Apr 4, 2022
20-FAnnual report for period ending Dec 31, 2020
Apr 27, 2021
20-FAnnual report for period ending Dec 31, 2019
Apr 24, 2020

Frequently asked questions

What is Innate Pharma SA's stock price?

Innate Pharma SA (IPHA) closed at $733.88 on Oct 9, 2026, up 1.74% from the previous close of $721.31.

How much revenue does Innate Pharma SA make?

Innate Pharma SA reported revenue of €9.01M for fiscal 2025, down 55.25% from fiscal 2024.

Sources and methodology

Fundamentals come from Innate Pharma SA's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures